OrthoPediatrics (NASDAQ:KIDS) Upgraded to “Hold” at Truist Financial

Truist Financial upgraded shares of OrthoPediatrics (NASDAQ:KIDS) to a hold rating in a report published on Thursday,Zacks reports.

KIDS has been the subject of several other reports. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Piper Sandler reiterated an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. BTIG Research reaffirmed a “buy” rating and set a $29.00 price objective on shares of OrthoPediatrics in a report on Monday, September 14th. Finally, Needham & Company LLC increased their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $26.44.

OrthoPediatrics Stock Down 2.6%

KIDS opened at $21.69 on Thursday. OrthoPediatrics has a twelve month low of $14.42 and a twelve month high of $26.74. The company’s 50-day moving average price is $22.76 and its two-hundred day moving average price is $19.50. The stock has a market cap of $566.33 million, a price-to-earnings ratio of -12.91 and a beta of 0.99. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. As a group, equities analysts expect that OrthoPediatrics will post -1.14 earnings per share for the current year.

Insider Activity

In related news, major shareholder Jennifer Pritzker sold 326,700 shares of the business’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the sale, the insider directly owned 6,536,764 shares in the company, valued at approximately $150,607,042.56. The trade was a 4.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David Pelizzon sold 326,700 shares of the stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $23.04, for a total value of $7,527,168.00. Following the sale, the director directly owned 6,536,764 shares in the company, valued at $150,607,042.56. This trade represents a 4.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 2,100,000 shares of company stock worth $46,747,931. 32.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On OrthoPediatrics

Several hedge funds have recently bought and sold shares of KIDS. Legal & General Group Plc purchased a new position in shares of OrthoPediatrics during the 2nd quarter valued at $34,000. Quantinno Capital Management LP purchased a new position in OrthoPediatrics during the first quarter worth about $160,000. Waverly Advisors LLC purchased a new position in OrthoPediatrics during the first quarter worth about $184,000. R Squared Ltd bought a new position in OrthoPediatrics in the 1st quarter worth about $212,000. Finally, Bank of America Corp DE bought a new position in OrthoPediatrics in the 2nd quarter worth about $268,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp. (NASDAQ: KIDS) develops, manufactures and sells orthopedic products designed specifically for children. The company focuses on addressing the distinct anatomical and clinical needs of pediatric patients, offering implants, instruments and related technologies for orthopedic surgery.

Its product portfolio includes solutions for pediatric trauma and deformity correction, scoliosis and spinal disorders, sports medicine, limb lengthening and reconstruction, and neuromuscular conditions.